UK and EU Supplement Compliance: Key Quality and Labelling Standards for Manufacturers

## Regulatory Baselines Across the UK and European Union Operating across the European and British dietary supplement sectors requires adherence to parallel statutory frameworks. Following the United Kingdom's departure from the European Union, regulatory divergence has established distinct administrative regimes, even where core technical baselines remain structurally aligned. For contract manufacturers, brand owners, and formulators distributing in both territories, compliance requires continuous monitoring of European Food Safety Authority (EFSA) opinions and UK Food Standards Agency (FSA) registers. Notably, under the Windsor Framework, Northern Ireland remains aligned with specific EU internal market rules, meaning Great Britain (GB)—England, Scotland, and Wales—operates the primary divergent regime. In both jurisdictions, food supplements are defined as concentrated sources of nutrients or other substances with a nutritional or physiological effect, marketed in pre-dosed forms such as capsules, tablets, pastilles, or ampoules. These products are categorised strictly under food law rather than medicinal product legislation. Formulations must not be presented as possessing properties for the treatment, prevention, or cure of human disease. Any product bearing therapeutic or medicinal claims falls under the statutory remit of the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK or the European Medicines Agency (EMA) alongside national competent authorities across EU member states, triggering pharmaceutical licensing requirements. ## Novel Foods and Permitted Substance Lists Ingredient validation represents the primary technical checkpoint during product development. In the European Union, Directive 2002/46/EC establishes harmonised positive lists of vitamins, minerals, and permitted chemical forms for use in food supplements. Conversely, botanicals, amino acids, and specific bioactive compounds remain largely governed by national legislation across individual member states, subject to mutual recognition unless restricted under Regulation (EC) No 1925/2006. Ingredients without a documented history of significant consumption within the UK or EU prior to 15 May 1997 fall under the Novel Food regime—governed by Regulation (EU) 2015/2283 in the EU and retained EU law managed via the FSA regulated products application service in Great Britain. Placing a novel ingredient on either market requires a formal dossier demonstrating that the substance poses no safety risk to public health, is not nutritionally disadvantageous, and does not mislead the consumer. Formulators must verify the regulatory classification of botanical extracts, synthetic isolates, and novel lipids prior to scale-up to mitigate risks of border detentions, import rejections, or commercial recalls. ## Health Claims Substantiation and Authorisation Packaging copy, digital marketing, and commercial promotional materials must adhere to statutory nutrition and health claim registries. Regulation (EC) No 1924/2006 governs claims within the EU, whilst the Great Britain Nutrition and Health Claims Register (GB NHC Register) applies to products marketed in England, Scotland, and Wales. Only authorised claims listed on these registers may be applied to finished products. Authorised health claims comprise Article 13 general function claims and Article 14 disease risk reduction or children's development claims. In both frameworks, permitted claims are strictly bound to specific scientific wording and defined conditions of use. For micronutrients, eligibility typically requires the presence of a 'significant amount'—defined under Regulation (EU) No 1169/2011 as a minimum of 15% of the daily Nutrient Reference Value (NRV) per recommended daily intake—maintained across the verified shelf life of the production batch. ## Quality Assurance and Analytical Verification Finished product compliance relies on verified Good Manufacturing Practice (GMP) protocols and robust Hazard Analysis Critical Control Point (HACCP) systems. Verification of raw material identity, botanical authenticity, and purity profiles must be confirmed via batch-specific Certificates of Analysis (CoAs) alongside secondary analytical testing. Quantitative release specifications should be verified using validated analytical techniques, including High-Performance Liquid Chromatography (HPLC) and Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Testing must demonstrate that active compounds meet declared label values within permitted European Commission tolerance guidelines, whilst ensuring contaminants—including heavy metals (lead, cadmium, mercury, and inorganic arsenic), polycyclic aromatic hydrocarbons (PAHs), and microbiological counts—remain below statutory maximum levels established under Regulation (EU) 2023/915 and retained GB equivalents. Finally, stability testing programmes conducted under standard ICH climatic conditions are required to substantiate labelled shelf lives and prevent nutrient degradation below declared claim thresholds.